Delcath Systems Inc.

Delcath Systems (Nasdaq:DCTH) announced today that it entered into a securities purchase agreement worth $7 million in proceeds.

The company entered into an agreement with certain accredited investors for the private placement. The collection of investors includes existing investors, Delcath executives and members of the board of directors.

Delcath plans to issue and sell 876,627 shares of common stock at a price of $3.72 apiece. To certain investors, it intends to sell just over one million pre-funded warrants in lieu of shares of common stock. Those warrants enable the purchase of up to just over a million shares of common stock at a price of $3.71 apiece.

Pre-funded warrants have an exercise price of 1¢ per share of common stock, according to a news release. They’re immediately exercisable and remain exercisable until exercised in full.

Delcath expects gross proceeds of approximately $7 million before deducting offering expenses payable b…

Delcath Systems (Nasdaq:DCTH) announced today that it closed its previously announced private placement worth $6.2 million.

The interventional oncology company issued and sold nearly 1.45 million shares of its common stock at $2.90 per share. In lieu of common stock, it sold 692,042 pre-funded warrants to purchase common stock. Price per warrant totaled $2.89. The pre-funded warrants hold an exercise price of 1¢ per share of common stock. They remain immediately exercisable now and until exercised in full.

New York-based Delcath intends to use net proceeds for working capital and other general corporate purposes, according to a news release.

The latest fundraising for Delcath adds to a securities purchase agreement worth approximately $5 million from July. The company also earmarked those proceeds for working capital and other general corporate purposes.

Delcath’s technology focuses on the treatment of primary and metastatic liver cancers. I…

Delcath Systems (Nasdaq:DCTH) announced today that it entered into a securities purchase agreement worth approximately $5 million.

The New York-based interventional oncology company developing treatments for primary and metastatic cancers of the liver will issue and sell 690,954 shares of common stock at a price per share of $3.98.

In lieu of shares of common stock, the company will offer 566,761 pre-funded warrants to purchase common stock at $3.97 per warrant, with an exercise price of 1¢ per share of common stock. The warrants will be immediately exercisable and remain exercisable until exercised in full, according to a news release.

Delcath expects gross proceeds of approximately $5 million, with the intention of using the funds for working capital and other general corporate purposes. The company expects the offering to close on or about July 20.

BTIG analyst Marie Thibault wrote in a report that analysts were “pleased to see Delcath wa…

Delcath Systems (OTC:DCTH) shares ticked up slightly despite first-quarter results that missed the consensus forecast.

The New York-based company posted losses of -$6.7 million, or -$1.04 per share, on sales of $388,000 for the three months ended March 31, 2021, for a -33% bottom-line slide on sales growth of 32%.

Delcath’s EPS of -$1.04 came in 6¢ behind Wall Street, where analysts were looking for sales of $400,000.

“The recently released preliminary results from the Focus trial strongly indicates that Hepzato’s benefit-risk ratio is a significant improvement versus an earlier generation of Delcath’s proprietary percutaneous hepatic perfusion system,” Delcath CEO Gerard Michel said in a news release. “We look forward to continued progress in the balance of the year, as we prepare both to file an NDA in early 2022 and expand the development of Hepzato into additional areas of high unmet need.”

Delcath did not offer financial guidance …